진시스템
Financials
Valuation Metrics
진시스템's Market Cap is ₩347B. At end of 2025 it was ₩349B. Ranked #1985 of 2,421 in KR market (top 82%), #1252 of 1,640 on KOSDAQ (top 76%), #212 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 92%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 34.67B KRW | KR#1,985/2,421 Sec#212/231 |
| Revenue | 1.01B KRW | KR#2,386/2,421 Sec#218/231 |
| Net Income | -12.72B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 17.70B KRW | KR#2,385/2,421 Sec#227/231 |
| Net Assets | 11.65B KRW | KR#2,362/2,421 Sec#223/231 |
| Employees | 69 | KR#1,887/2,421 Sec#163/231 |
| Value | ||
| P/B | 2.98x | KR#2,107/2,421 Sec#166/231 |
| P/S | 34.33x | KR#2,362/2,421 Sec#193/231 |
| FCF Yield | -20.49% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -109.20% | KR#2,352/2,421 Sec#220/231 |
| ROA | -71.87% | KR#2,384/2,421 Sec#222/231 |
| Op. Margin | -777.39% | KR#2,377/2,421 Sec#210/231 |
| Revenue Growth | -4.59% | KR#1,751/2,421 Sec#167/231 |
| Financial Health | ||
| Debt Ratio | 51.95% | KR#984/2,421 Sec#115/231 |
| Total Debt | 3.72B KRW | KR#1,836/2,421 Sec#177/231 |
| FCF | -7.10B KRW | KR#1,597/2,421 Sec#132/231 |
| Cash | 4.06B KRW | KR#2,085/2,421 Sec#194/231 |
| Current Ratio | 3.59x | KR#444/2,421 Sec#67/231 |
| Performance | ||
| 1Y Return | -32.08% | KR#1,621/2,421 Sec#129/231 |
| 1M Return | 1.75% | KR#1,052/2,421 Sec#78/231 |
| From 52W High | -43.87% | KR#1,098/2,421 Sec#79/231 |
| 1Y MDD | -57.15% | KR#1,316/2,421 Sec#108/231 |
| Trading | ||
| Volume | 5,973 shares | KR#2,087/2,421 Sec#201/231 |
| Trading Value | 24.3M KRW | KR#2,098/2,421 Sec#209/231 |
| Foreign Own. | 0.96% | KR#2,053/2,421 Sec#200/231 |
| Per Share | ||
| EPS | -1,495 KRW | KR—/2,421 Sec—/231 |
| BPS | 1,369 KRW | KR#2,223/2,421 Sec#197/231 |
Company Info
GeneSystem was established in 2010 to commercialize a rapid PCR technology-based platform and was listed on KOSDAQ in 2021. The company specializes in molecular diagnostic equipment and diagnostic kits, expanding its business primarily in Europe and Asia, and experienced growth in developing country markets post-2020 pandemic. It pursues market entry by diversifying rapid platform technology-based testing solutions and employing a two-track B2B strategy, continuously releasing respiratory disease diagnostic content for the post-COVID era to drive global market adoption. Headquartered in Yuseong-gu, Daejeon, GeneSystem was founded in 2010.